H.C. Wainwright lowered the firm’s price target on Valneva to $20 from $23 and keeps a Buy rating on the shares following the investor day. The firm cites more conservative initial sales estimates for Ixchiq and VLA15 for the target cut. The analyst believes Valneva’s lyme disease vaccine is a potential blockbuster.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN:
Questions or Comments about the article? Write to editor@tipranks.com